Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Nyack, NY
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Nyack, NY
Click here to add this to my saved trials
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Hickory, NC
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Hickory, NC
Click here to add this to my saved trials
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
High Point, NC
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
High Point, NC
Click here to add this to my saved trials
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Winston-Salem, NC
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Canton, OH
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Canton, OH
Click here to add this to my saved trials
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Cincinnati, OH
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Massillon, OH
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Massillon, OH
Click here to add this to my saved trials
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Middletown, OH
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Middletown, OH
Click here to add this to my saved trials
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Lancaster, PA
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Lancaster, PA
Click here to add this to my saved trials
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Langhorne, PA
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Langhorne, PA
Click here to add this to my saved trials
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Reading, PA
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Reading, PA
Click here to add this to my saved trials
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Upland, PA
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Upland, PA
Click here to add this to my saved trials
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
West Reading, PA
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
West Reading, PA
Click here to add this to my saved trials
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Willow Grove, PA
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Willow Grove, PA
Click here to add this to my saved trials
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Hilton Head Island, SC
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Hilton Head Island, SC
Click here to add this to my saved trials
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Myrtle Beach, SC
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Nashville, TN
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Bryan, TX
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Bryan, TX
Click here to add this to my saved trials
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Corpus Christi, TX
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Abingdon, VA
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Abingdon, VA
Click here to add this to my saved trials
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Lynchburg, VA
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Lynchburg, VA
Click here to add this to my saved trials
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Kennewick, WA
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Kennewick, WA
Click here to add this to my saved trials
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Spokane, WA
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated:  12/5/2017
mi
from
Hobart,
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status: Enrolling
Updated: 12/5/2017
mi
from
Hobart,
Click here to add this to my saved trials
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated:  12/5/2017
New England Cancer Specialists
mi
from
Scarborough, ME
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated: 12/5/2017
New England Cancer Specialists
mi
from
Scarborough, ME
Click here to add this to my saved trials
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated:  12/5/2017
AnMedical Health Cancer Center
mi
from
Anderson, SC
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated: 12/5/2017
AnMedical Health Cancer Center
mi
from
Anderson, SC
Click here to add this to my saved trials
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated:  12/5/2017
University of Florida
mi
from
Gainesville, FL
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated: 12/5/2017
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated:  12/5/2017
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated: 12/5/2017
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated:  12/5/2017
Genesis Medical Center - West Campus
mi
from
Davenport, IA
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated: 12/5/2017
Genesis Medical Center - West Campus
mi
from
Davenport, IA
Click here to add this to my saved trials
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated:  12/5/2017
University of Iowa
mi
from
Iowa City, IA
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated: 12/5/2017
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated:  12/5/2017
Covenant Cancer Treatment Center
mi
from
Waterloo, IA
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated: 12/5/2017
Covenant Cancer Treatment Center
mi
from
Waterloo, IA
Click here to add this to my saved trials
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated:  12/5/2017
Nevada Cancer Research Foundation
mi
from
Las Vegas, NV
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated: 12/5/2017
Nevada Cancer Research Foundation
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated:  12/5/2017
Margaret R Pardee Memorial Hospital
mi
from
Hendersonville, NC
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated: 12/5/2017
Margaret R Pardee Memorial Hospital
mi
from
Hendersonville, NC
Click here to add this to my saved trials
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated:  12/5/2017
St. Joseph Hospital of Orange
mi
from
Orange, CA
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated: 12/5/2017
St. Joseph Hospital of Orange
mi
from
Orange, CA
Click here to add this to my saved trials
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated:  12/5/2017
Yale University
mi
from
New Haven, CT
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated: 12/5/2017
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated:  12/5/2017
Mount Sinai Comprehensive Cancer Center
mi
from
Miami Beach, FL
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated: 12/5/2017
Mount Sinai Comprehensive Cancer Center
mi
from
Miami Beach, FL
Click here to add this to my saved trials
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated:  12/5/2017
Memorial Health University Medical Center
mi
from
Savannah, GA
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated: 12/5/2017
Memorial Health University Medical Center
mi
from
Savannah, GA
Click here to add this to my saved trials
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated:  12/5/2017
Cancer Care Specialists of Illinois - Decatur Memorial Hospital
mi
from
Decatur, IL
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated: 12/5/2017
Cancer Care Specialists of Illinois - Decatur Memorial Hospital
mi
from
Decatur, IL
Click here to add this to my saved trials
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated:  12/5/2017
Edward Hospital Cancer Center
mi
from
Naperville, IL
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated: 12/5/2017
Edward Hospital Cancer Center
mi
from
Naperville, IL
Click here to add this to my saved trials
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated:  12/5/2017
Norton Cancer Institute - Norton HealthCare Pavilion
mi
from
Louisville, KY
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated: 12/5/2017
Norton Cancer Institute - Norton HealthCare Pavilion
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated:  12/5/2017
Tulane University Health Sciences Center
mi
from
New Orleans, LA
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated: 12/5/2017
Tulane University Health Sciences Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated:  12/5/2017
Berkshire Medical Center Cancer and Infusion Center
mi
from
Pittsfield, MA
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated: 12/5/2017
Berkshire Medical Center Cancer and Infusion Center
mi
from
Pittsfield, MA
Click here to add this to my saved trials
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated:  12/5/2017
Breslin Cancer Center
mi
from
Lansing, MI
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated: 12/5/2017
Breslin Cancer Center
mi
from
Lansing, MI
Click here to add this to my saved trials
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated:  12/5/2017
Missouri Valley Cancer Consortium
mi
from
Omaha, NE
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated: 12/5/2017
Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated:  12/5/2017
Monmouth Medical Center
mi
from
Long Branch, NJ
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated: 12/5/2017
Monmouth Medical Center
mi
from
Long Branch, NJ
Click here to add this to my saved trials
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated:  12/5/2017
Newark Beth Israel Medical Center
mi
from
Newark, NJ
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated: 12/5/2017
Newark Beth Israel Medical Center
mi
from
Newark, NJ
Click here to add this to my saved trials
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated:  12/5/2017
Community Medical Center, Inc
mi
from
Toms River, NJ
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated: 12/5/2017
Community Medical Center, Inc
mi
from
Toms River, NJ
Click here to add this to my saved trials
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated:  12/5/2017
Waverly Hematology Oncology
mi
from
Cary, NC
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated: 12/5/2017
Waverly Hematology Oncology
mi
from
Cary, NC
Click here to add this to my saved trials
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated:  12/5/2017
First Health of the Carolinas Cancer Center
mi
from
Pinehurst, NC
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated: 12/5/2017
First Health of the Carolinas Cancer Center
mi
from
Pinehurst, NC
Click here to add this to my saved trials
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated:  12/5/2017
Toledo Clinic Cancer Center
mi
from
Toledo, OH
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Status: Enrolling
Updated: 12/5/2017
Toledo Clinic Cancer Center
mi
from
Toledo, OH
Click here to add this to my saved trials